Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06874842 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 1, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date changed from estimate of Mar 14, 2025 to Mar 13, 2025v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Secondary endpoints: details revised at 2 of 9 entries
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
Trial Details
NCT Number NCT06874842
Lead Sponsor Guangzhou Patronus Biotech Co., Ltd.
Conditions
(from sponsor)		 Herpes Zoster (HZ)
Related terms Chickenpox, Herpes Zoster
Enrollment 92 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov